Rix-Fp
Hemophilia
National Taiwan University HospitalPhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the Hemophilia cohort.
View all 34 →
Same molecule, other indications
Rix-Fp is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →